Vitruvias Therapeutics Recalls Thyroid Tablets Due to Superpotency Risk

• by Shimanta Das
• August 26, 2026

In a significant safety alert, Vitruvias Therapeutics, based in Auburn, Alabama, has announced a nationwide recall of one lot of its Thyroid Tablets, USP 30 mg. The recall, initiated on August 24, 2026, and published by the U.S. Food and Drug Administration (FDA), was prompted by testing that revealed the tablets could be superpotent, meaning they contain a higher concentration of active ingredients than intended. This poses a potential health risk to patients who rely on this medication for thyroid hormone replacement therapy.

The affected product, Thyroid Tablets, USP 30 mg, is a natural hormone preparation derived from porcine thyroid glands. It contains both levothyroxine and liothyronine and is commonly prescribed to treat hypothyroidism, a condition where the thyroid gland does not produce enough hormones. The recall is specifically for lot number 504950, which was distributed nationwide. Patients who have this specific lot are urged to check their medication bottles and contact their healthcare provider or pharmacist for guidance.

Importantly, the company is warning patients not to simply stop taking the medication on their own. Abruptly discontinuing thyroid hormone replacement can lead to serious health complications, including worsening of hypothyroid symptoms such as fatigue, weight gain, and depression. Instead, patients should consult their healthcare provider to discuss alternative treatment options or obtain a replacement prescription. The FDA and Vitruvias Therapeutics are working to ensure that all affected products are removed from the market and that patients receive appropriate care.

This recall is part of a broader pattern of medication safety issues, as seen with recent recalls of other products like Momchipz Veggie Chips and Whole Foods Mild Guacamole. While these recalls are unrelated, they highlight the importance of rigorous quality control in the pharmaceutical and food industries. Patients who have questions or concerns about this recall can contact Vitruvias Therapeutics directly or visit the FDA’s website for more information. The company is committed to patient safety and is taking all necessary steps to address this issue promptly.